Expansion Therapeutics
10996 Torreyana Road
Suite 280
San Diego
CA
92121
United States
Tel: (858) 764-4290
Website: http://www.expansionrx.com/
About Expansion Therapeutics
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. We are initially focused on expansion repeat disorders, a set of ~30 genetic diseases for which there are no satisfactory therapies. Our lead disease focus, myotonic dystrophy type 1 (DM1), is the most frequent cause of adult onset muscular dystrophy. Expansion has assembled an initial focused pipeline of compositions targeting repeats that drive a number of expansion repeat disorders. For more information or to apply for this position, please visit our website htttps://www.expansionrx.com
9 articles about Expansion Therapeutics
-
Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors
1/19/2022
Expansion Therapeutics, Inc. today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director.
-
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here's a look.
-
Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases
9/29/2021
Expansion Therapeutics, Inc today announced the close of an $80 million Series B financing.
-
Expansion said much of the funds will go into its SMiRNA platform to find clinical candidates in myotonic DM1, FTD, ALS, and several other tauopathies.
-
Expansion Therapeutics Names Mark Ledeboer, Ph.D., Senior Vice President of Drug Discovery
6/14/2021
Expansion Therapeutics, Inc., today announced the appointment of Mark Ledeboer, Ph.D. to Senior Vice President of Drug Discovery.
-
Expansion Therapeutics Names Valerie Cullen, Ph.D., Senior Vice President of Research
5/6/2021
Expansion Therapeutics, Inc., a biotechnology company advancing transformative medicines to patients with RNA-mediated diseases, today announced the appointment of Valerie Cullen, Ph.D., to Senior Vice President of Research.
-
Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President
10/5/2020
Expansion Therapeutics, Inc., a biotechnology company advancing transformative medicines to patients with RNA-mediated diseases, today announced the appointment of Renato Skerlj, Ph.D., as the company’s new Chief Executive Officer and President, effective immediately. Dr. Skerlj will
-
Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies Targeting RNA-mediated Diseases
1/24/2019
Companies Initiate Lead Optimization Program Leveraging the Origenis AI Discovery Platform to Identify RNA-targeted Small Molecule Compounds for Development
-
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.